Trends in Helicobacter pylori resistance to clarithromycin: from phenotypic to genomic approaches

• Autor(a) principal: Marques, Andreia T.
• Data de Publicação: 2020
• Outros Autores: Vítor, Jorge M.B., Santos, Andrea, Oleastro, Mónica, Vale, Filipa F.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.18/7609
• topic: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Genome, Bacterial; Genomics; Helicobacter Infections; Helicobacter pylori; High-Throughput Nucleotide Sequencing; Phenotype; RNA, Ribosomal, 23S; Infecções Gastrointestinais

For a long time Helicobacter pylori infections have been treated using the macrolide antibiotic, clarithromycin. Clarithromycin resistance is increasing worldwide and is the most common cause of H. pylori treatment failure. Here we review the mechanisms of antibiotic resistance to clarithromycin, detailing the individual and combinations of point mutations found in the 23S rRNA gene associated with resistance. Additionally, we consider the methods used to detect clarithromycin resistance, emphasizing the use of high-throughput next-generation sequencing methods, which were applied to 17 newly sequenced pairs of H. pylori strains isolated from the antrum and corpus of a recent colonized paediatric population. This set of isolates was composed of six pairs of resistant strains whose phenotype was associated with two point mutations found in the 23S rRNA gene: A2142C and A2143G. Other point mutations were found simultaneously in the same gene, but, according to our results, it is unlikely that they contribute to resistance. Further, among susceptible isolates, genomic variations compatible with mutations previously associated with clarithromycin resistance were detected. Exposure to clarithromycin may select low-frequency variants, resulting in a progressive increase in the resistance rate due to selection pressure.